Evidence map›Paper›PMID 40665233›Full record

Observational studyBMC infectious diseases2025

Experience of research nurses with oral encochleated amphotericin B for treatment of cryptococcal meningitis in a resource-limited setting.

Cynthia Ahimbisibwe, Richard Kwizera, Jane Frances Ndyetukira, Olivie Carolyne Namujju, Alisat Sadiq, Mucunguzi Atukunda, Caleb P Skipper, David R Boulware, David B Meya

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04031833 (Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04031833 phase1 / phase2completednot on this map

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial

TypeinterventionalSponsorMatinas BioPharma Nanotechnologies, Inc.Ran2019 to 2023Enrolled178ConditionsCryptococcal MeningitisArmsMAT2203, Amphotericin B
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cynthia AhimbisibweInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Richard KwizeraInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. kwizerarichard@ymail.com.
Jane Frances NdyetukiraInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Olivie Carolyne NamujjuInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Alisat SadiqInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Mucunguzi AtukundaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Caleb P SkipperDepartment of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN, USA.
David R BoulwareDepartment of Medicine, Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN, USA.
David B MeyaInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBesides the commonly used intravenous formulations of amphotericin B, an oral nanocrystal amphotericin B (MAT2203) formulation is being evaluated for efficacy to treat invasive fungal infections. This new experimental oral formulation has not been used before.

methodsHerein, we describe our experiences with using oral amphotericin B for management of patients with HIV-associated cryptococcal meningitis in Uganda from a research nurse perspective.

resultsWe found oral amphotericin B a better alternative to intravenous amphotericin B deoxycholate due to less toxicity, mostly limited to gastrointestinal-related toxicities only. We clinically observed no drug reactions like rigors, phlebitis, and less vomiting among patients on oral amphotericin B as compared to those on intravenous amphotericin B deoxycholate. Subjectively, meningitis symptoms of patients on oral amphotericin B seemed to overall clinically improve more rapidly compared to those receiving intravenous amphotericin B deoxycholate. Few adverse events were observed. A novel challenge with oral amphotericin was difficulty in monitoring adherence for the night doses in the absence of the healthcare providers.

conclusionsOral amphotericin B was generally safe and well tolerated. However, it requires some training for the nurse, patient and care takers for better administration, adherence and treatment outcomes.

trial registrationThis was observational sub-study that was nested under the EnACT trial. The EnACT trial was registered prospectively. ClincalTrials.gov: NCT04031833; Registration date: July 24, 2019; Last verified: March 31, 2023.

Indexed as

Amphotericin BAntifungal AgentsMeningitis, CryptococcalAdministration, OralAdultDeoxycholic AcidDrug CombinationsFemaleHumansMaleMiddle AgedNursesResource-Limited SettingsTreatment OutcomeUgandaAmphotericin Bamphotericin B, deoxycholate drug combinationAntifungal AgentsDeoxycholic AcidDrug CombinationsAmphotericin BClinical researchCryptococcal meningitisResearch nurseUganda

Identifiers

PMID40665233
PMCPMC12265374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.